In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...
As Emergent BioSolutions continues to pawn off manufacturing real estate in its pivot from production specialist to full-time ...
The company has been selling off its assets after an error caused tens of millions of vaccines to get thrown out during the ...
Syngene International has acquired its first US manufacturing facility for approximately USD 50 million. The acquisition aims ...
Bangalore: Syngene International Limited, a global contract research, development, and manufacturing organization (CRDMO), ...
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading ...
When markets resume trading today, City Union Bank, Navin Fluorine, Syngene International, IIFL Finance, NLC India, Sharda ...